stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Orexo AB (publ)

Sweden · Stockholm: ORX.ST · Market cap: · P/E: · P/S:

Orexo is a specialty pharmaceutical company that makes and sells medicines for opioid addiction, pain, and emergency overdose situations.

Orexo makes medicines that help people break free from opioid addiction — and, increasingly, medicines that save them when they overdose. Its main product is Zubsolv, a dissolvable tablet placed under the tongue that eases withdrawal and cravings for people hooked on opioids. The company sells mostly in the United States, where the addiction crisis is enormous, and it also has products for pain and for emergency use, including a nasal spray that reverses opioid overdoses.

Orexo AB (ORX.ST) AmorphOX drug delivery technology: line art illustration of A small vial of white pharmaceutical powder beside a dissolving tablet showing fine powder particles
AmorphOX powder technology
AmorphOX is a powder-based technology Orexo uses to make drugs easier for the body to absorb.

The business is built on a simple bet: addiction medicine is hard to make and heavily regulated, so the companies that do it well face few rivals. Orexo develops its own formulations, patents them, and gets them approved by regulators — that approval is the moat. Doctors and patients choose Zubsolv partly because it dissolves quickly and tastes better than older options, which matters when you're asking a struggling patient to take a medicine every day. But this is not a cozy business. Orexo has leaned heavily on Zubsolv, and that dependence is risky: the addiction-treatment market is dominated by bigger rivals, and generic competition and pricing pressure can hit hard. Orexo has fought long patent battles in the U.S. to protect Zubsolv from cheaper copycat versions, and those fights have cost real money and created real uncertainty. The company is profitable at times and loss-making at others, and it has spent years trying to build a second leg of growth through new products and partnerships rather than relying on one pill.


Orexo is headquartered in Uppsala, Sweden, and its shares trade on Nasdaq Stockholm. Its strategy is essentially to turn its specialty know-how into a pipeline — new addiction and rescue medicines that can carry the company when the old ones face competition. Whether that gamble pays off depends on getting new products approved and sold before Zubsolv's pricing erodes further.

Saved answer · last researched 16 Nov 2026